Cardiol Therapeutics Inc. (NASDAQ:CRDL) to Post Q1 2024 Earnings of ($0.06) Per Share, HC Wainwright Forecasts

Cardiol Therapeutics Inc. (NASDAQ:CRDL) – Investment analysts at HC Wainwright issued their Q1 2024 EPS estimates for shares of Cardiol Therapeutics in a research note issued on Monday, April 22nd. HC Wainwright analyst V. Bernardino expects that the company will post earnings of ($0.06) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for Cardiol Therapeutics’ Q2 2024 earnings at ($0.05) EPS, Q3 2024 earnings at ($0.05) EPS, Q4 2024 earnings at ($0.04) EPS, FY2024 earnings at ($0.20) EPS, FY2025 earnings at ($0.25) EPS, FY2026 earnings at ($0.34) EPS, FY2027 earnings at ($0.09) EPS and FY2028 earnings at $0.43 EPS.

Cardiol Therapeutics Trading Up 3.4 %

Shares of CRDL stock opened at $1.82 on Wednesday. Cardiol Therapeutics has a 1 year low of $0.55 and a 1 year high of $2.17. The firm has a fifty day moving average price of $1.70 and a 200-day moving average price of $1.20. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.36 and a quick ratio of 4.36. The company has a market cap of $124.27 million, a price-to-earnings ratio of -5.52 and a beta of 0.95.

Cardiol Therapeutics (NASDAQ:CRDL) last issued its quarterly earnings data on Monday, April 1st. The company reported ($0.09) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Cardiol Therapeutics

A hedge fund recently raised its stake in Cardiol Therapeutics stock. Laird Norton Trust Company LLC grew its holdings in shares of Cardiol Therapeutics Inc. (NASDAQ:CRDL) by 63.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 100,000 shares of the company’s stock after acquiring an additional 38,673 shares during the period. Laird Norton Trust Company LLC owned about 0.15% of Cardiol Therapeutics worth $90,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 12.49% of the stock is currently owned by hedge funds and other institutional investors.

About Cardiol Therapeutics

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19, as well as for the treatment of recurrent pericarditis and acute myocarditis.